InvestorsObserver
×
News Home

Will Ligand Pharmaceuticals Inc. (LGND) Outperform the Healthcare Sector?

Thursday, September 24, 2020 11:39 AM | InvestorsObserver Analysts

Mentioned in this article

Will Ligand Pharmaceuticals Inc. (LGND) Outperform the Healthcare Sector?

Ligand Pharmaceuticals Inc. (LGND) is near the top in its sector according to InvestorsObserver.

LGND gets an overall rating of 59. That means it scores higher than 59% of stocks.

Ligand Pharmaceuticals Inc. gets a 77 rank in the Healthcare sector. Healthcare is number 3 out of 11 sectors.

Overall Score - 59
LGND has an Overall Score of 59. Find out what this means to you and get the rest of the rankings on LGND!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style.

Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Ligand Pharmaceuticals Inc. Stock Today?

Ligand Pharmaceuticals Inc. (LGND) stock is trading at $94.50 as of 11:35 AM on Thursday, Sep 24, a gain of $1.32, or 1.42% from the previous closing price of $93.18. The stock has traded between $91.24 and $96.71 so far today. Volume today is light. So far 120,982 shares have traded compared to average volume of 255,870 shares.

Click Here to get the full Stock Score Report on Ligand Pharmaceuticals Inc. (LGND) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App